|
1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ryan DP, Hong TS and Bardeesy N:
Pancreatic adenocarcinoma. N Engl J Med. 371:1039–1049. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Vincent A, Herman J, Schulick R, Hruban RH
and Goggins M: Pancreatic cancer. Lancet. 378:607–620. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Diener MK, Combs SE and Buchler MW:
Chemoradiotherapy for locally advanced pancreatic cancer. Lancet
Oncol. 14:269–270. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Finger EC and Giaccia AJ: Hypoxia,
inflammation, and the tumor microenvironment in metastatic disease.
Cancer Metastasis Rev. 29:285–293. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Matsumoto S, Yasui H, Mitchell JB and
Krishna MC: Imaging cycling tumor hypoxia. Cancer Res.
70:10019–10023. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Milane L, Ganesh S, Shah S, Duan ZF and
Amiji M: Multi-modal strategies for overcoming tumor drug
resistance: Hypoxia, the Warburg effect, stem cells, and
multifunctional nanotechnology. J Control Release. 155:237–247.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Thorens B and Mueckler M: Glucose
transporters in the 21st Century. Am J Physiol Endocrinol Metab.
298:E141–E145. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Adekola K, Rosen ST and Shanmugam M:
Glucose transporters in cancer metabolism. Curr Opin Oncol.
24:650–654. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Szablewski L: Expression of glucose
transporters in cancers. Biochim Biophys Acta. 1835:164–169.
2013.PubMed/NCBI
|
|
11
|
Krzeslak A, Wojcik-Krowiranda K, Forma E,
Jozwiak P, Romanowicz H, Bienkiewicz A and Brys M: Expression of
GLUT1 and GLUT3 glucose transporters in endometrial and breast
cancers. Pathol Oncol Res. 18:721–728. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wincewicz A, Sulkowska M, Koda M,
Kanczuga-Koda L, Witkowska E and Sulkowski S: Significant
coexpression of GLUT-1, Bcl-xL and Bax in colorectal cancer. Ann N
Y Acad Sci. 1095:53–61. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Chiba I, Ogawa K, Morioka T, Shimoji H,
Sunagawa N, Iraha S, Nishimaki T, Yoshimi N and Murayama S:
Clinical significance of GLUT-1 expression in patients with
esophageal cancer treated with concurrent chemoradiotherapy. Oncol
Lett. 2:21–28. 2011.PubMed/NCBI
|
|
14
|
Ohba S, Fujii H, Ito S, Fujimaki M,
Matsumoto F, Furukawa M, Yokoyama J, Kusunoki T, Ikeda K and Hino
O: Overexpression of GLUT-1 in the invasion front is associated
with depth of oral squamous cell carcinoma and prognosis. J Oral
Pathol Med. 39:74–78. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Brophy S, Sheehan KM, McNamara DA, Deasy
J, Bouchier-Hayes DJ and Kay EW: GLUT-1 expression and response to
chemoradiotherapy in rectal cancer. Int J Cancer. 125:2778–2782.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Rastogi S, Banerjee S, Chellappan S and
Simon GR: Glut-1 antibodies induce growth arrest and apoptosis in
human cancer cell lines. Cancer Lett. 257:244–251. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Alakus H, Batur M, Schmidt M, Drebber U,
Baldus SE, Vallböhmer D, Prenzel KL, Metzger R, Bollschweiler E,
Hölscher AH and Mönig SP: Variable 18F-fluorodeoxyglucose uptake in
gastric cancer is associated with different levels of GLUT-1
expression. Nucl Med Commun. 31:532–538. 2010.PubMed/NCBI
|
|
18
|
Edge SB and Compton CC: The American Joint
Committee on Cancer: The 7th edition of the AJCC cancer staging
manual and the future of TNM. Ann Surg Oncol. 17:1471–1474. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Reynolds T: Declaration of Helsinki
revised. J Natl Cancer Inst. 92:1801–1803. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Böhning D, Böhning W and Holling H:
Revisiting Youden's index as a useful measure of the
misclassification error in meta-analysis of diagnostic studies.
Stat Methods Med Res. 17:543–554. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Cho H, Lee YS, Kim J, Chung JY and Kim JH:
Overexpression of glucose transporter-1 (GLUT-1) predicts poor
prognosis in epithelial ovarian cancer. Cancer Invest. 31:607–615.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Sulkowska M, Wincewicz A, Sulkowski S,
Koda M and Kanczuga-Koda L: Relations of TGF-beta1 with HIF-1
alpha, GLUT-1 and longer survival of colorectal cancer patients.
Pathology. 41:254–260. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Mayer A, Schmidt M, Seeger A, Serras AF,
Vaupel P and Schmidberger H: GLUT-1 expression is largely unrelated
to both hypoxia and the Warburg phenotype in squamous cell
carcinomas of the vulva. BMC Cancer. 14:7602014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Melstrom LG, Salabat MR, Ding XZ, Strouch
MJ, Grippo PJ, Mirzoeva S, Pelling JC and Bentrem DJ: Apigenin
down-regulates the hypoxia response genes: HIF-1α, GLUT-1 and VEGF
in human pancreatic cancer cells. J Surg Res. 167:173–181. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Fraga A, Ribeiro R and Medeiros R: Tumor
hypoxia: The role of HIF. Actas Urol Esp. 33:941–951. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Pugachev A, Ruan S, Carlin S, Larson SM,
Campa J, Ling CC and Humm JL: Dependence of FDG uptake on tumor
microenvironment. Int J Radiat Oncol Biol Phys. 62:545–553. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Huang T, Civelek AC, Li J, Jiang H, Ng CK,
Postel GC, Shen B and Li XF: Tumor microenvironment-dependent
18F-FDG, 18F-fluorothymidine, and 18F-misonidazole uptake: A pilot
study in mouse models of human non-small cell lung cancer. J Nucl
Med. 53:1262–1268. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Jiang J, Tang YL and Liang XH: EMT: A new
vision of hypoxia promoting cancer progression. Cancer Biol Ther.
11:714–723. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Osinsky S, Zavelevich M and Vaupel P:
Tumor hypoxia and malignant progression. Exp Oncol. 31:80–86.
2009.PubMed/NCBI
|
|
30
|
Lee HE, Kim MA, Lee BL and Kim WH: Low
Ki-67 proliferation index is an indicator of poor prognosis in
gastric cancer. J Surg Oncol. 102:201–206. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Viale G, Giobbie-Hurder A, Regan MM,
Coates AS, Mastropasqua MG, Dell'Orto P, Maiorano E, MacGrogan G,
Braye SG, Ohlschlegel C, et al: Prognostic and predictive value of
centrally reviewed Ki-67 labeling index in postmenopausal women
with endocrine-responsive breast cancer: Results from breast
international group trial 1–98 comparing adjuvant tamoxifen with
letrozole. J Clin Oncol. 26:5569–5575. 2008.
|
